Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 3/20 | 0.42 |
| ▸ | TGM2 | P21980 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | UBE2M | P61081 | 2/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19597031 | 1.00 | PTPRB (0.46) | PTPRBALDH1A1POLBHTTTDP1 | |
| SCHEMBL17708324 | 0.88 | MAPT (0.46) | PTPRBALDH1A1HTTF13A1TGM2 | |
| SCHEMBL16276104 | 0.87 | EGFR (0.47) | ALDH1A1POLBTDP1F13A1TGM2 | |
| SCHEMBL16276114 | 0.87 | EGFR (0.47) | ALDH1A1POLBTDP1F13A1TGM2 | |
| SCHEMBL16276131 | 0.87 | F13A1 (0.57) | ALDH1A1POLBHTTTDP1F13A1 | |
| SCHEMBL16276108 | 0.84 | USP2 (0.51) | ALDH1A1POLBF13A1TGM2NPC1 | |
| SCHEMBL16276130 | 0.83 | ALDH1A1 (0.47) | ALDH1A1HTTTDP1F13A1TGM2 | |
| SCHEMBL16276133 | 0.81 | SMN1; SMN2 (0.46) | ALDH1A1HTTNPC1RAB9AKMT2A | |
| SCHEMBL16276132 | 0.81 | THRB (0.46) | ALDH1A1HTTTDP1F13A1TGM2 | |
| SCHEMBL17676841 | 0.81 | ALDH1A1 (0.44) | PTPRBALDH1A1HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630957-B2 | 2,3-butanediamide epoxide compound and preparation method and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-04-25 | — | — | US | disclosed |
| US-9630957-B2 | 2,3-butanediamide epoxide compound and preparation method and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-04-25 | — | — | US | disclosed |
| US-20160115160-A1 | 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2016-04-28 | — | — | US | disclosed |
| US-20160115160-A1 | 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2016-04-28 | — | — | US | disclosed |
| WO-2014190899-A1 | 2,3-BUTANEDIAMIDE EPOXIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF | 中国人民解放军军事医学科学院毒物药物研究所 (CN) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115160-A1 | 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof | ECE2, GNE, EPHX2 | PTPRB 4379/4885ALDH1A1 446/4885POLB 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.